Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
oxaliplatin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stomach Neoplasms
1 trial -
pectin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Crohn's Disease
1 trial -
pemetrexed
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Brain Metastases
1 trial -
rabbit ATG, Cyclosporine, Levamisole
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Aplastic Anemia
1 trial -
recombinant human erythropoietin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hypoxic-Ischemic Encephalopathy
1 trial -
recombinant human erythropoietin (rhEpo)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Infant, Premature
1 trial -
rhGM-CSF
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pulmonary Alveolar Proteinosis
1 trial -
sarcosine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Schizophrenia
1 trial -
self-expandable 125I radioactive seeds-loaded-stent
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholangiocellular Carcinoma
1 trial -
sintilimab+IBI310+chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC Stage II
1 trial -
sintiliman plus LDRT
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric Cancer
1 trial -
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Influenza
2 trials -
standard triple region
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Helicobacter Pylori Infection
1 trial -
the standard "3+7" regimen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Newly Diagnosed Acute Myeloid Leukemia (AML)
1 trial -
tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastric
1 trial -
tislelizumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Stage III
1 trial -
umbilical cord mesenchymal stem cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral Arterial Disease
1 trial -
umbilical cord mesenchymal stem cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cartilage Damage
1 trial -
vitamin C
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Carcinoma, Non-Small-Cell Lung
1 trial -
zanubrutinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Antiphospholipid Syndrome
1 trial -
zoledronic acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Congenital Dyserythropoietic Anemia (CDA)
1 trial -
11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
HPV Infection
1 trial -
1mg KHK7580
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy Volunteer
1 trial -
ASC30
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Weight Management
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources